Login/Register
  • 中文
  • English

A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy

DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Taiwan
Partnership wanted
Introduction
A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy
Features / strengths
A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy
Specification in detail
Preclinical development
Preclinical development
Site-Specific Antibody-Drug Conjugate B7-H3 Cancer Therapy
Information
Introduction
A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy
Features / strengths
A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy
Specification in detail
Preclinical development
Preclinical development
Site-Specific Antibody-Drug Conjugate B7-H3 Cancer Therapy

A Site-Specific Antibody-Drug Conjugate Targeting B7-H3 for Cancer Therapy

DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Taiwan
Like() | Mark as favorites
Share：
DEVELOPMENT CENTER FOR BIOTECHNOLOGY Other products
Development of KRAS-degrader drugs against cancer

Small-Molecule Drugs

Anti-Globo H mAb for Cancer Therapy

Protein Drugs

Globo H-targeted CAR-T cells for solid tumor therapy

Protein Drugs

TIM-3 antibody in preclinical studies for Cancer Immunotherapy

Protein Drugs

UB-941: A Selective & Orally Active Raf Kinase Inhibitor as a Precision Medicine

Small-Molecule Drugs

Development of Novel Selective FPR1 Antagonist Against Neutrophil Related Inflammatory Disease

Small-Molecule Drugs

Development of Novel ADC Targeting Neurotensin receptor-1 (NTSR1) for Head and Neck Cancer Therapy

Protein Drugs

Recommended
Nanobody based Trispecific Antibody of T cell Engager with Dual ICP Targets, Nb-TriTE (SOA101)

Shine-On BioMedical Co., Ltd

Ropeginterferon alfa 2b

Pharmaessentia Corp.

Nanobody based Trispecific Antibody of T cell Engager with Dual ICP Targets, Nb-TriTE (SOA101)

China Medical University & Healthcare System

Drug Substance Manufacturing

Amaran Biotechnology, Inc.

Request more info